Welcome to our dedicated page for INSMED SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
INSMED Inc Chair and CEO William Lewis reported a series of equity transactions in company common stock. He exercised stock options covering 10,699 shares at exercise prices of $17.16 and $30.46 per share and sold 10,699 shares of common stock in multiple open-market transactions at prices ranging from approximately $116.01 to $118.80 per share. The sales were effected pursuant to a pre-established Rule 10b5-1 trading plan. Lewis also reports 233,924 shares of common stock held indirectly by a trust.
INSM filed a Form 144 reporting proposed sales of Common Stock by an affiliate. The filing lists multiple proposed dispositions by William Lewis, including sales on 04/16/2026, 05/04/2026, 05/13/2026, 05/18/2026, 06/03/2026, 06/08/2026, and 06/25/2026, with individual share quantities shown for each date.
INSMED Inc's Chief Medical Officer, Martina Flammer, reported an exercise-and-sell transaction in company stock. She exercised stock options to acquire a total of 12,302 shares of common stock at strike prices of $19.74 and $29.13 per share, then sold the same 12,302 shares in open-market trades at weighted average prices of $110.60 and $109.02 per share. These trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 27, 2025, and she now holds 60,486 shares of common stock directly.
Insmed Inc. reported Form 144 filings reporting insider sales. The filing lists sales by Martina Flammer of Common stock on 05/11/2026 (12,949 shares), 05/13/2026 (7,854 shares), 05/14/2026 (10,479 shares), 06/03/2026 (2,566 shares), and 06/05/2026 (1,858 shares).
The filing identifies these as sales under Stock Plan Activity and lists the transactions as Issuer-related on 07/06/2026. The document provides transaction dates and share counts; it does not state proceeds, prices, or remaining beneficial ownership in the excerpt provided.
INSMED Inc Chair and CEO William Lewis reported option exercises and share sales in INSMED common stock. On June 25, 2026, he exercised stock options covering 21,398 shares at strike prices of $17.16 and $30.46 per share, converting derivative awards into common stock.
On the same date, he sold 21,398 shares in multiple open-market transactions at weighted average prices ranging from about $101.78 to $106.45 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. After these transactions, Lewis holds 258,917 shares directly and 233,924 shares indirectly through a trust.
Insmed Inc. insider William Lewis submitted a Form 144 reporting proposed dispositions of Common Stock. The filing lists multiple sale dates and share quantities reported under "Securities Sold During The Past 3 Months," including 6,515 shares on 06/08/2026, 7,605 shares on 06/03/2026, and earlier entries in May and April 2026.
INSMED Inc senior vice president Samuele Butera received new equity awards as part of his compensation. He was granted 7,342 Restricted Stock Units, each representing one future share of common stock, with 25% vesting on the first day of the first month after the first anniversary of grant and the remainder vesting in three annual installments.
He was also granted stock options for 12,570 shares of common stock at an exercise price of $102.15 per share, expiring on June 23, 2036. These options vest 25% on the initial vesting date and 12.5% every six months thereafter until fully vested. All awards were granted for no cash consideration.
INSMED Inc executive files initial insider report with no transactions. Samuele Butera, listed as SVP, GM, Global Respiratory at INSMED Inc, is identified as a reporting person on a Form 3. The filing shows zero buy, sell, acquisition, or disposition transactions, and no derivative positions or holdings are reported.
INSMED Inc Chief Legal Officer Michael Alexander Smith sold 1,806 shares of Common Stock in an open-market transaction. The shares were sold at a price of $95.82 per share. After this sale, he directly holds 37,648 shares of INSMED Inc Common Stock.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which means the timing and amount were set in advance rather than decided at the moment of sale.
INSM filed Form 144 disclosing proposed sales of Common Stock by an insider and issuer stock plan activity. The filing lists multiple proposed dispositions by Michael Smith: 1,959 (appears as 1,959?), sorry—must use exact counts from the excerpt: the excerpt shows sale entries of 2,159 on 06/03/2026, 6,149 on 05/22/2026, 4,109 on 05/13/2026, and 19,638 on 03/30/2026. The filing also records stock plan activity dated 06/01/2026. These entries are disclosures of planned or reported dispositions; cash‑flow treatment and prices are not included in the excerpt.